drugset / Trial / NCT00368134

To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

NCT00368134

Phase 3 Completed 370 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the efficacy, safety and tolerability of vildagliptin compared to voglibose in patients with type 2 diabetes. Please note this study is not being conducted in the United States.

Timeline

Start
2006-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 50 mg